<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03481465</url>
  </required_header>
  <id_info>
    <org_study_id>HEP_10PAFIP</org_study_id>
    <nct_id>NCT03481465</nct_id>
  </id_info>
  <brief_title>Searching for Early Biomarkers of Long-term Hepatic, Metabolic and Endothelial Dysfunction in Non-affective Psychosis</brief_title>
  <official_title>Searching for Early Biomarkers of Long-term Hepatic, Metabolic and Endothelial Dysfunction in Non-affective Psychosis. A 10-year Follow-up Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Marques de Valdecilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Investigación Marqués de Valdecilla</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Consorcio Centro de Investigación Biomédica en Red, M.P.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Marques de Valdecilla</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate, at long-term, the occurrence of liver disease and&#xD;
      cardio-vascular risk, in a sample of patients diagnosed with first episode of non-affective&#xD;
      psychosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Schizophrenia is a severe brain disorder with an excess mortality and reduced life&#xD;
      expectancy. It has been proposed that around 60% of this excess mortality is due to physical&#xD;
      pathology, mostly cardio-metabolic disorders. In addition to the deleterious effects of&#xD;
      hypercaloric diet and sedentary lifestyle, the use of antipsychotic medication has itself a&#xD;
      significant effect on metabolism. The metabolic disturbances described related to&#xD;
      antipsychotic exposure include weight gain and obesity, dyslipemia, and insulin-resistance or&#xD;
      new onset diabetes mellitus, representing cardio-metabolic risk factors leading to&#xD;
      cardio-vascular events at the long-run. Some of these metabolic disturbances have been&#xD;
      described as relevant factors for non-alcoholic fatty liver disease (NAFLD) development.&#xD;
      NAFLD is accepted to be the hepatic component of the metabolic syndrome, and it has been&#xD;
      described as an independent cardiovascular risk factor. A recent study by our group found a&#xD;
      significant increase in the prevalence of hepatic steatosis after 3 years of antipsychotic&#xD;
      treatment in a sample of patients with psychosis. Other studies proposed that there is a link&#xD;
      between NAFLD and severe cardio-vascular disease that may be early predicted through&#xD;
      peripheral microvascular system signs (endothelial dysfunction). Interestingly, recent&#xD;
      studies have shown the presence of endothelial dysfunction in psychosis, probably related to&#xD;
      antipsychotic-exposure. In summary, the investigators consider of relevance the study of a&#xD;
      possible interrelation between metabolic syndrome, NAFLD, and endothelial dysfunction, at&#xD;
      long-term, and their probable correlation with antipsychotic exposure.&#xD;
&#xD;
      Based on the available scientific evidence, the investigators hypothesize that the long-term&#xD;
      exposure to antipsychotic medication would be related to liver disease and endothelial&#xD;
      dysfunction.&#xD;
&#xD;
      The research project would be implemented as part of a larger prospective longitudinal study&#xD;
      on first episode non-affective psychosis, in the First Episode Psychosis Clinical Program&#xD;
      (PAFIP). In particular, the project would be part of the &quot;10 PAFIP study&quot;, in which those&#xD;
      patients that had been included in the PAFIP program 10 years ago will be extensively&#xD;
      evaluated (e.g.: clinical, neuroimaging, neuro-psychological, and metabolic evaluations) in&#xD;
      order to analyse the long-term progress of the psychosis.&#xD;
&#xD;
      Steatosis and fibrosis indexes would be determined for 10-years time point. For those&#xD;
      patients with scores predicting hepatic fibrosis, a full hepatic examination, including&#xD;
      elastometry assessment (FibroScan®) with controlled attenuation parameter (CAP) and abdominal&#xD;
      ultrasound would be carried out. Moreover, endothelial function would be examined, using&#xD;
      EndoPAT2000® and carotid ultrasound evaluation, for those patients turning 10 years since&#xD;
      their antipsychotic treatment was firstly prescribed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">February 12, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of Non-Alcoholic Fatty Liver Disease (NAFLD) diagnosed by transient elastography (FibroScan®) by spirometry.</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The presence of endothelial dysfunction measured by EndoPAT2000®.</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Psychosis</condition>
  <condition>Metabolic Syndrome</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals included in the Longitudinal Long-term Study of First Episode Psychosis&#xD;
        Clinical Program (10-PAFIP) at the University Hospital Marqués de Valdecilla (Santander -&#xD;
        Cantabria).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients followed in the First Episode Psychosis Clinical Program (PAFIP) from&#xD;
             February 2001 to December 2007.&#xD;
&#xD;
          -  Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)&#xD;
             criteria of brief psychotic disorder, schizophreniform disorder, schizophrenia or&#xD;
             schizoaffective disorder.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Meeting DSM-IV criteria for drug dependence.&#xD;
&#xD;
          -  Meeting DSM-IV criteria for mental retardation.&#xD;
&#xD;
          -  Having a history of neurological disease or head injury.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier Vázquez Bourgon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto de Investigación Marqués de Valdecilla</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>March 19, 2018</study_first_submitted>
  <study_first_submitted_qc>March 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2018</study_first_posted>
  <last_update_submitted>December 14, 2020</last_update_submitted>
  <last_update_submitted_qc>December 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundación Marques de Valdecilla</investigator_affiliation>
    <investigator_full_name>Benedicto Crespo-Facorro</investigator_full_name>
    <investigator_title>Associate Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Biomarkers</keyword>
  <keyword>Hepatic dysfunction</keyword>
  <keyword>Metabolic dysfunction</keyword>
  <keyword>Endothelial dysfunction</keyword>
  <keyword>Antipsychotics</keyword>
  <keyword>Non-alcoholic fatty liver disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

